<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00058279</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000287211</org_study_id>
    <secondary_id>NCI-03-C-0109</secondary_id>
    <nct_id>NCT00058279</nct_id>
    <nct_alias>NCT00055211</nct_alias>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>MDX-CTLA4 Combined With IL-2 for Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the&#xD;
      immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white&#xD;
      blood cells to kill tumor cells. Combining monoclonal antibody therapy with interleukin-2 may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combining monoclonal antibody therapy&#xD;
      with interleukin-2 in treating patients who have metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of anti-cytotoxic T-lymphocyte-associated&#xD;
           antigen-4 monoclonal antibody (MDX-CTLA4) in combination with high-dose interleukin-2&#xD;
           (IL-2) in patients with metastatic melanoma. (Phase I is closed to accrual as of&#xD;
           4/13/2004).&#xD;
&#xD;
        -  Determine the activity of MDX-CTLA4 administered at the MTD with high-dose IL-2 in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine whether the administration of IL-2 alters the pharmacokinetics of MDX-CTLA4 in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the safety and adverse event profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of anti-cytotoxic&#xD;
      T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-CTLA4).&#xD;
&#xD;
        -  Phase I: Patients receive MDX-CTLA4 IV on days 0, 21, and 42. Patients also receive&#xD;
           high-dose interleukin-2 (IL-2) IV over 15 minutes every 8 hours for up to 15 doses&#xD;
           beginning on days 22 and 43. Treatment repeats every 63 days for up to 3 courses in the&#xD;
           absence of disease progression or unacceptable toxicity. Patients with an ongoing&#xD;
           partial response and no greater than grade 1 toxicity may receive additional courses of&#xD;
           therapy. Patients who require discontinuation of MDX-CTLA4 due to toxicity may continue&#xD;
           receiving IL-2 at the discretion of the investigator.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of MDX-CTLA4 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. (Phase I is closed to accrual as of&#xD;
      4/13/2004).&#xD;
&#xD;
        -  Phase II: Patients receive treatment as in phase I at the MTD of MDX-CTLA4. Patients who&#xD;
           achieve a partial or complete response and later develop recurrent or progressive&#xD;
           disease may be retreated at the same dose.&#xD;
&#xD;
      Patients are followed at 3 weeks, every 3 months for 1 year, every 6 months for 2 years, and&#xD;
      then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-51 patients (3-18 for phase I and 19-33 for phase II) will be&#xD;
      accrued for this study within 1 year. (Phase I is closed to accrual as of 4/13/2004).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Intraocular Melanoma</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IV melanoma&#xD;
&#xD;
               -  Mucosal or ocular melanoma also eligible&#xD;
&#xD;
          -  Clinically evaluable disease&#xD;
&#xD;
               -  At least 1 site of measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 2,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Hematocrit at least 30%&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)* (less than 3.0 mg/dL in&#xD;
             patients with Gilbert's syndrome)&#xD;
&#xD;
          -  AST no greater than 3 times ULN*&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody nonreactive&#xD;
&#xD;
          -  No evidence or history of significant hepatic disease that would preclude safe&#xD;
             administration of high-dose IL-2 NOTE: *Unless attributable to disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  No evidence or history of significant renal disease that would preclude safe&#xD;
             administration of high-dose IL-2&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No evidence or history of significant cardiac disease that would preclude safe&#xD;
             administration of high-dose IL-2&#xD;
&#xD;
          -  Thallium stress test normal (for patients over 50 years of age or with a history of&#xD;
             cardiovascular disease)&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No evidence or history of significant pulmonary disease that would preclude safe&#xD;
             administration of high-dose IL-2&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No autoimmune disease (including uveitis and autoimmune inflammatory eye disease)&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  No evidence or history of significant gastrointestinal disease that would preclude&#xD;
             safe administration of high-dose IL-2&#xD;
&#xD;
          -  No evidence or history of psychiatric disease that would preclude safe administration&#xD;
             of high-dose IL-2&#xD;
&#xD;
          -  No other underlying medical condition that would make the administration of the study&#xD;
             drug hazardous or obscure the interpretation of adverse events&#xD;
&#xD;
          -  No other concurrent medical condition that would preclude study entry&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 weeks since prior immunotherapy for melanoma and recovered&#xD;
&#xD;
          -  No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody&#xD;
             (MDX-CTLA4)&#xD;
&#xD;
          -  No prior high-dose (at least 600,000 IU/kg every 8 hours) interleukin-2 (IL-2)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy for melanoma and recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 3 weeks since prior hormonal therapy for melanoma and recovered&#xD;
&#xD;
          -  At least 4 weeks since prior corticosteroids&#xD;
&#xD;
          -  No concurrent systemic or topical corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy for melanoma and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent immunosuppressive agents (e.g., cyclosporine or its analog)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005 Dec;12(12):1005-16. Epub 2005 Oct 21.</citation>
    <PMID>16283570</PMID>
  </results_reference>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>ciliary body and choroid melanoma, small size</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

